25th Jul 2014 09:56
LONDON (Alliance News) - Tissue Regenix Group PLC said Friday it has been granted a European patent for the use of its dCELL technology to create tissue implants for bladder repair.
The company said it has access to a range of patents protecting its core processes in major markets, and is adding to these with its technology partner, the University of Leeds, to protect individual products and processes.
The dCELL process removes DNA and other cellular material from animal and human tissues to create a tissue scaffold that can then be used to repair diseased or worn-out body parts.
"As part of the global roll-out of our dCELL® technology, this latest European bladder patent adds to our ever-growing global portfolio, and helps Tissue Regenix achieve our aim of commercialising new ways to treat an array of urological disorders," Chief Executive Antony Odell said in a statement.
Shares in Tissue Regenix were trading down 0.5% at 26.98 pence Friday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group